- Invion’s licensed PhotosoftTM technology receives patent protection until 2033
- PhotosoftTM targeted as a therapy for a range of cancers including ovarian, lung, skin and prostate cancer
Melbourne, Australia, 10 September 2018: ASX-listed life sciences company Invion Limited (ASX:IVX) announces the grant in Australia of the patent for chlorin e4 sodium, a new generation photodynamic therapy over which Invion has exclusive commercialisation rights in Australia and New Zealand.
Chlorin e4 sodium is a photosensitising agent used in photodynamic therapy (PDT). PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen to kill malignant cells, shut down tumours and stimulate the immune system. In contrast to surgery, radiotherapy and chemotherapy that are largely immunosuppressant, Invion’s early clinical data demonstrates a positive whole body immune response.
PhotosoftTM is the trademark for chlorin e4 sodium, for which The Cho Group, a Hong Kong based group that has successfully commercialised a number of advanced technologies, has been granted a patent by IP Australia. Patent number 2013357030, titled “Chlorin derivative useful in photodynamic therapy and diagnosis” will be in force until 2033.
Invion has been appointed by The Cho Group to lead the global clinical development of the PhotosoftTM technology as a cancer therapy.
Invion chief executive Dr Greg Collier said the patent provides protection for the PhotosoftTM intellectual property and supports Invion’s program to manufacture a number of new topical and intravenous formulations of PhotosoftTM for the treatment of all cancers, including lung, prostate, ovarian and skin cancer.
“As there is an ongoing need for better photosensitisers, Invion’s technology uses its patented photosentiser combined with a laser light activation in the near infrared (NIR) peaks of absorption to achieve a deeper tissue penetration that targets increased treatment efficacy. The new topical and intravenous PhotosoftTM formulations are being designed to address the limitations of prior PDT therapies, and also providing a positive whole-body immune response treatment for patients,” Dr Collier said.
The current calendar year 2018 period has been defined by the Company’s strong progress in line with Invion’s strategy to develop and commercialise the licensed PhotosoftTM technology, with activities directed towards human clinical trials ramping up from Q1 2019.
Activities of noteworthy significance include:
- The technical transfer of the PhotosoftTM technology to a recognised Australian GLP production facility is complete, and the first Australian batch of the active ingredient (IVX-P02) will be available in the coming weeks.
- Scientific research and analysis at the Hudson Institute of Medical Research has confirmed that the PhotosoftTM technology is rapidly and potently active against ovarian cancer cells. These early results are important as ovarian cancers have a 5-year mortality rate greater than 70%, and patients almost universally develop recurrent, chemo-resistant disease. New therapies are urgently needed and this data lays the groundwork for preclinical trials of the PhotosoftTM technology as potential future therapy for this disease.
- Invion has engaged with expert pharmaceutical formulators to produce new topical and intravenous products suitable for use in skin cancer and in solid tumours, such as those present in ovarian, prostate and lung cancer.
- Discussions with thought leaders and specialist Australian oncologists have identified significant clinical opportunities in these cancer types and the design of the clinical study protocols is underway.
Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program. Further results of Invion’s early studies into ovarian cancer will be presented at the Australian Society for Biochemistry and Molecular Biology (ASBMB)’s ComBio Conference being held in Sydney from 23-26 September 2018. Invion is listed on ASX (ASX:IVX).